Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT

被引：0
作者：
Deborah M. Broadbent
Amu Wang
Christopher P. Cheyne
Marilyn James
James Lathe
Irene M. Stratton
John Roberts
Tracy Moitt
Jiten P. Vora
Mark Gabbay
Marta García-Fiñana
Simon P. Harding
机构：
[1] University of Liverpool,Department of Eye and Vision Science, Institute of Life Course and Medical Sciences
[2] Member of Liverpool Health Partners,St Paul’s Eye Unit
[3] Liverpool University Hospitals Foundation Trust,Department of Biostatistics
[4] Member of Liverpool Health Partners,Division of Rehabilitation, Ageing and Wellbeing, School of Medicine
[5] University of Liverpool,Gloucestershire Retinal Research Group
[6] Member of Liverpool Health Partners,Department of Diabetes and Endocrinology
[7] Clinical Trials Research Centre,Department of Health Services Research
[8] University of Nottingham,undefined
[9] Cheltenham General Hospital,undefined
[10] Mersey Diabetes Support Group,undefined
[11] Royal Liverpool University Hospital,undefined
[12] University of Liverpool,undefined
[13] Member of Liverpool Health Partners,undefined
[14] Brownlow Health Centre,undefined
[15] Member of Liverpool Health Partners,undefined
来源：
Diabetologia | 2021年 / 64卷
关键词：
Diabetic retinopathy; Individualised; Personalised; Risk-based; Screening; Systematic; Variable interval;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：56 / 69
页数：13
相关论文
共 89 条
[11]  
Looker HC(2008)The shift to personalised and population medicine J Diabetes Sci Technol 2 335-341
[12]  
Nyangoma SO(2013)Individualised screening for diabetic retinopathy: the ISDR study—rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval Lancet 382 200-201
[13]  
Cromie DT(2019)Grading and disease management in national screening for diabetic retinopathy in England and Wales BMJ Open 9 e025788-971
[14]  
Grauslund J(2003)Individualised variable interval risk-based screening for sight threatening diabetic retinopathy—the Liverpool Risk Calculation Engine Diabet Med 20 965-2182
[15]  
Andersen N(2017)Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement Diabetologia 60 2174-2604
[16]  
Andresen J(2012)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) JAMA 308 2594-1736
[17]  
Agardh E(2011)Multi-attribute health status classification systems. Health Utilities Index Qual Life Res 20 1727-502
[18]  
Tababat-Khani P(1995)eq5dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L Pharmacoeconomics 7 490-415
[19]  
Stratton IM(2018)Modelling valuations for EuroQol health states Stata J 18 395-1108
[20]  
Aldington SJ(1997)Multiple imputation using chained equations: issues and guidance for practice Med Care 35 1095-399
123456789